One EGPA patient on methotrexate medication (#1) additionally had mepolizumab for maintenance therapy, a monoclonal antibody against interleukin-5, for his eosinophilic vasculitis. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.